Log in

Statement Regarding Vaccine Induced Prothrombotic Immune Thrombocytopenia after COVID‐19 Vaccination

7 Apr 2021 9:43 AM | Valerie Orton (Administrator)

from Leanne Berkahn (President), Steven Lane (Vice President), on behalf of the HSANZ Council and Nada Hamad, HSANZ Member.

The Haematology Society of Australia and New Zealand is aware of a number of case reports of Vaccine-induced Prothrombotic Immune Thrombocytopenia (VIPIT) following AstraZeneca COVID-19 Vaccination. This is a rapidly evolving field and the clinical data are still emerging. HSANZ aims to facilitate dissemination of information as it becomes available. 

The HSANZ will not comment on individual cases however, the following resources may be useful in supporting clinicians and patients. The content and recommendations are not specifically endorsed by HSANZ. Our webpage will be updated as more information/resources emerge.

2nd April 2021 TGA Media Release: Specific Clotting Condition reported after COVID-19 Vaccination 
2nd April 2021 ATAGI media release: ATAGI statement on COVID-19 vaccination and a reported case of thrombosisCOVID-19 Advisory for Ontario Canada VIPIT Guidance

British Society of Haematology VIPIT Guidance

German Thrombosis and Haemostasis Society VIPIT Guidance

The Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) has released a statement on the testing of VIPIT in Australia and New Zealand. For the full statement please go to the HSANZ Members only site.


Haematology Society of Australia and New Zealand (HSANZ)
145 Macquarie Street, Sydney NSW 2000
Tel: 02 8097 8114


Copyright © 2020 Haematology Society of Australia & New Zealand (HSANZ). All Rights Reserved.

Powered by Wild Apricot Membership Software